2021
DOI: 10.2174/1574885516666210315100848
|View full text |Cite
|
Sign up to set email alerts
|

Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach

Abstract: Objective: Adequate glycemic control in diabetes patients requires oral combination therapy. Saxagliptin is a dipeptidyl peptidase-4 inhibitor having less adverse effects and metformin is a first line medicine for diabetes treatment. The aim of this research work is to develop a bilayer tablet of saxagliptin and metformin in fixed dose combination (FDC) using quality by design (QbD) to acquire immediate release of saxagliptin and sustained release of metformin from bilayer tablet to ultimately achieve superior… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 66 publications
0
0
0
Order By: Relevance